This seminar is a joint organization of Leuven.Inc and Leuven Medical Technology Center (L-MTC).
Controlling the rate and extent of drug release from dosage forms after they have been administered to patients, is important to minimize fluctuations in drug plasma concentration and to ensure a uniform therapeutic effect. Moreover, controlled drug delivery contributes to patient comfort and compliance.
This seminar will highlight research and development activities in the field of controlled drug delivery both in academia as well as in pharmaceutical industry.
Date: Tuesday October 2nd, 2012
Location: Thermotechnisch Instituut, Kasteelpark Arenberg, 3001 Leuven (Heverlee)
|13h30:||Registration and coffee|
|14h00:||Welcome and introduction by Leuven.Inc|
|14h10:||General introduction of the topic and chairman of the day
Guy Van den Mooter, Prof. KU Leuven, Laboratory for Pharmacotechnology and Biopharmacy
|14h40:||Polymers designed for drug delivery
Jennifer Patterson, Assistant Prof. KU Leuven, Department of Metallurgy and Materials Engineering
|15h10:||Durable polymer stent drug release: The dynamics of drug release revealed by correlated confocal raman and atomic force microscopy on a drug-eluting stent
Cynthia Maryanoff, PhD, Product and Process Scientific Solutions Johnson & Johnson
|16h10:||Bioabsorbable polymer drug release: Visualizing drug release from a drug-eluting stent for both in vitro and in vivo samples
Cynthia Maryanoff, PhD, Product and Process Scientific Solutions, Johnson & Johnson
|16h40:||Mesoporous silica to make poorly soluble drugs bioavailable
Johan Martens, Prof. KU Leuven, Centre for Surface Chemistry and Catalysis
|17h00:||Controlled release technologies in the management of pain: a clinical perspective
Bart Morlion, Prof. and Director Leuven Center for Algology & Pain Management
|17h30:||Nanocrystals for prolonged parenteral drug delivery
Nicolas Darville, KU Leuven Laboratory for Pharmacotechnology and Biopharmacy – IWT Baekelandt
|18h00:||Q & A|
|18h30:||Drinks and networking|
The interventions will be held in English.
Abstracts of the presentations can be found underneath.
|60 euro (excl. VAT): researchers affiliated and billable to academic institutes
120 euro (excl. VAT): members of Leuven.Inc
160 euro (excl. VAT): all others
Participation in our activities at -50% discount via KMO-portefeuille
Registrations before Wednesday September 26th, 2012, preferably via the online registration form (use the 'Register' button) or by email to email@example.com (including all contact and invoice details).
After registration you will receive a confirmation and route description. The registration fee is payable after receipt of invoice. Cancellation after subscription is not possible. However, replacement by a colleague is allowed.*
* As an (Associate) Company Member you can be replaced by a colleague. As an individual Member you can only be replaced by another Individual Member. When this is not possible, Leuven.Inc will charge an extra fee for the replacement by a non-member.
Mesoporous silica to make poorly soluble drugs bioavailable - Johan Martens, Prof. KU Leuven, Centre for Surface Chemistry and Catalysis
“Estimates are that around 40% of drugs on the market and 90% of those in discovery pipelines exhibit poor aqueous solubility. The inherent low and variable oral bioavailability of poorly soluble active pharmaceutical ingredients presents an important challenge to drug development. Deposition of poorly soluble drugs into the pores of mesoporous silica offers the possibility to overcome their dissolution rate limited oral bioavailability. Desorption of the drugs from the silica surface upon contact with the gastrointestinal fluids is associated with the generation of drug concentrations that create the necessary driving force for absorption.”
Durable polymer stent drug release: The dynamics of drug release revealed by correlated confocal raman and atomic force microscopy on a drug-eluting stent - Cynthia Maryanoff, PhD, Product and Process Scientific Solutions Johnson & Johnson
Drug release from and coating morphology on a CYPHER® Sirolimus-eluting Coronary Stent (SES) during in vitro elution was studied by correlated confocal Raman and atomic force microscopy (CRM and AFM respectively). Chemical surface and subsurface maps of the SES were generated in the same region of interest by CRM and correlated with surface topography measured by AFM at different elution times. For the first time, a direct correlation between drug-rich regions and coating morphology was made on a drug-eluting medical device, linking drug release with pore formation, pore throats, and pore networks.
Bioabsorbable polymer drug release: Visualizing drug release from a drug-eluting stent for both in vitro and in vivo samples - Cynthia Maryanoff, PhD, Product and Process Scientific Solutions, Johnson & Johnson
The NEVO™ Sirolimus-eluting Coronary Stent (SES) incorporates hundreds of small reservoirs, each acting as a depot for drug delivery. It contains a bioabsorbable polymer matrix composed of PLGA with the proven therapeutic agent for the treatment of restenosis, sirolimus. We developed quantitative methodologies by CRM or FTIR to predict the average concentration of components (drug, polymer and excipients) within the reservoir inlay and applied them to in vitro and in vivo polymer degradation samples to characterize the drug release and polymer erosion as a function of time.
Controlled release technologies in the management of pain: a clinical perspective - Bart Morlion, Prof. and Director Leuven Center for Algology & Pain Management
Controlled release technologies have improved effective pharmacological pain management and patient adherence. Some examples will be discussed: long acting opioid oral and transdermal drug delivery systems for cancer pain, patient controlled pump systems for postoperative analgesia and implantable computerized drug delivery systems for long-term management of chronic pain.
Nanocrystals for prolonged parenteral drug delivery - Nicolas Darville, KU Leuven Laboratory for Pharmacotechnology and Biopharmacy – IWT Baekelandt
Sustained release formulations for parenteral administration, especially injectable drug nanosuspensions, have recently emerged as promising alternatives to oral dosage forms. However, the industrial development of such long-acting suspensions currently remains driven by a trial and error approach. In order to ensure a rational and efficient formulation design in the future, acquirement of the missing knowledge of the in vivo formulation behavior and drug release mechanisms is indispensable.